In the field of respiratory clinical practice, the importance of measuring carbon dioxide (CO₂) concentrations cannot be overemphasized. Within the body, assessment of the arterial partial pressure of CO₂ (PaCO₂) has been the gold standard for many decades. Non-invasive assessments are usually predicated on the measurement of CO₂ concentrations in the air, usually using an infrared analyzer, and these data are clearly important regarding climate changes as well as regulations of air quality in buildings to ascertain adequate ventilation. Measurements of CO₂ production with oxygen consumption yield important indices such as the respiratory quotient and estimates of energy expenditure, which may be used for further investigation in the various fields of metabolism, obesity, sleep disorders, and lifestyle-related issues. Measures of PaCO₂ are nowadays performed using the Severinghaus electrode in arterial blood or in arterialized capillary blood, while the same electrode system has been modified to enable relatively accurate non-invasive monitoring of the transcutaneous partial pressure of CO₂ (PtcCO₂). PtcCO₂ monitoring during sleep can be helpful for evaluating sleep apnea syndrome, particularly in children. End-tidal PCO₂ is inferior to PtcCO₂ as far as accuracy, but it provides breath-by-breath estimates of respiratory gas exchange, while PtcCO₂ reflects temporal trends in alveolar ventilation. The frequency of monitoring end-tidal PCO₂ has markedly increased in light of its multiple applications (e.g., verify endotracheal intubation, anesthesia or mechanical ventilation, exercise testing, respiratory patterning during sleep, etc.).

Objectives A meta-analysis suggested that the use of varenicline, which is a partial agonist of nicotinic acetylcholine receptors and is effective in smoking cessation, increases the risk of cardiovascular events within 52 weeks of starting treatment. Defining these events as occurring during drug treatment (usually for 12 weeks) or within 30 days of discontinuation, another meta-analysis showed that the risk was statistically insignificant. In the present study, we aimed to clarify the effect of varenicline-assisted smoking cessation on vascular endothelial function assessed by flow-mediated vasodilation (FMD). Design Before–after and time-series. Setting Tochigi Prefecture, Japan. Participants Data of 85 participants who visited nicotine-dependent outpatient services were reviewed. FMD was repeatedly measured in 33 of the 85 participants. Inclusion criteria: 20 years and older, Brinkman index ≥200, Tobacco Dependence Screener ≥5 and stated motivation to quit smoking. Interventions Each participant was treated with varenicline titrated up to 1.0 mg twice daily (for 12 weeks in total). Primary and secondary outcome measures Participants were evaluated by FMD prior to, and 3 months after, complete smoking cessation. Follow-up FMD measurements were carried out every 3 months if possible. Changes in FMD during varenicline use were also evaluated. Results FMD was significantly increased from 4.0±1.8% to 5.5±2.2% (p<0.01, n=22) 3 months after complete cessation. Although the timecourse of FMD in most of the cases showed an increase with fluctuations, there was an exceptional case where FMD decreased over the 9 months following complete cessation. Although statistically insignificant, FMD also increased during varenicline use (from 3.7±2.7% to 4.3±2.8%, n=11). Conclusions Our observations suggest that in ceasing smokers, varenicline and smoking cessation do not lead to a worsening of the vascular endothelial function. Trial registration FK-79 (International University of Health and Welfare).

Background: Usual clinical practice for arterial blood gas analysis (BGA) in conscious patients involves a one-time arterial puncture to be performed after a resting period of 20–30 min. The aim of this study was to evaluate the use of transcutaneous BGA for estimating this gold standard arterial BGA.Methods: Spontaneously breathing Asian adults (healthy volunteers and respiratory patients) were enrolled (n = 295). Transcutaneous PO₂(PtcO₂) and PCO₂(PtcCO₂) were monitored using a transcutaneous monitor (TCM4, Radiometer Medical AsP, Denmark) with sensors placed on the chest, forearm, earlobe or forehead. Transcutaneous BGA at 1-min intervals was compared with arterial BGA at 30 min. Reasonable steps to find severe hypercapnia with PaCO₂ > 50 mmHg were evaluated.Results: Sensors on the chest and forearm were equally preferred and used because of small biases (n = 272). The average PCO₂bias was close to 0 mmHg at 4 min, and was almost constant (4–5 mmHg) with PtcCO₂being higher than PaCO₂at ≥8 min. The limit of agreement for PCO₂narrowed over time: ± 13.6 mmHg at 4 min, ± 7.5 mmHg at 12–13 min, and ± 6.3 mmHg at 30 min. The limit of agreement for PO₂also narrowed over time (± 23.1 mmHg at 30 min). Subgroup analyses showed that the PaCO₂and PaO₂levels, gender, and younger age significantly affected the biases. All hypercapnia subjects with PaCO₂ > 50 mmHg (n = 13) showed PtcCO₂ ≥ 50 mmHg for until 12 min.Conclusions: Although PtcCO₂is useful, it cannot completely replace PaCO₂because PCO₂occasionally showed large bias. On the other hand, the prediction of PaO₂using PtcO₂was unrealistic in Asian adults. PtcCO₂ ≥ 50 mmHg for until 12 min can be used as a screening tool for severe hypercapnia with PaCO₂ > 50 mmHg.